Please login to the form below

Not currently logged in
Email:
Password:

pimavanserin

This page shows the latest pimavanserin news and features for those working in and with pharma, biotech and healthcare.

Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

By a vote of 12 to 2, the advisory committee concluded that the benefits of Nuplazid (pimavanserin) outweigh its risks in PDP, setting up a possible FDA approval by the scheduled

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Srdjan Stankovic joins Acadia Pharmaceuticals Srdjan Stankovic joins Acadia Pharmaceuticals

    Nuplazid (pimavanserin), Acadia's lead candidate, has been submitted to the US FDA for a licence to treat Parkinson's disease psychosis, a condition that currently has no approved treatment.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics